Investor Relations

ABOUT ALDEYRA

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidates are first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Featured Video

Recent News

February 11, 2020
Live Webcast Scheduled to Begin at Noon ET Monday, February 24, 2020 LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 11, 2020-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients ...
January 28, 2020
Nationally Recognized Expert in Dry Eye Disease, Allergic Conjunctivitis, and Other Ocular Surface Diseases LEXINGTON, Mass. --(BUSINESS WIRE)--Jan. 28, 2020-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation ...
View All

Contact Us

Investor Relations Contact 

Scott Solomon
Sharon Merrill Associates
Senior Vice President
EMAIL: ALDX@investorrelations.com
PHONE: 857-383-2409

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video